Search
JBPOS0101
go.drugbank.com/drugs/DB16034InvestigationalJBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSepantronium
go.drugbank.com/drugs/DB17062InvestigationalSepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.
Categories: P-glycoprotein substratesAnacaulase
go.drugbank.com/drugs/DB17449ApprovedInvestigationalAnacaulase (anacaulase-bcdb) is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (Ananas comosus [L.] Merr.). It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lecti...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsNix-0699
go.drugbank.com/drugs/DB17732ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsVoxelotor
go.drugbank.com/drugs/DB14975ApprovedVoxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesAvacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin fragment C5a and its cognate C5aR receptor
Categories: Complement 5a Receptor Antagonist, P-glycoprotein substratesFluciclovine
go.drugbank.com/drugs/DB15237InvestigationalFluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).
Categories: P-glycoprotein inhibitorsTovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigationalTovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, wi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersBesigomsin
go.drugbank.com/drugs/DB20894ExperimentalBesigomsin is a small molecule drug. Besigomsin has a monoisotopic molecular weight of 416.18 Da.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEnerisant
go.drugbank.com/drugs/DB20605ExperimentalThe usage of the INN stem '-isant' in the name indicates that Enerisant is a histamine H3 receptor antagonist. Enerisant has a monoisotopic molecular weight of 398.23 Da.
Categories: P-glycoprotein substrates